拉夏貝爾(06116.HK)上月累增7宗訴訟案件 涉案金額1,268萬人幣
拉夏貝爾(06116.HK)公布,自5月1至31日,公司及子公司累計新增訴訟案件7宗,新增訴訟涉案金額約1,268萬元人民幣(下同)。
截至5月31日,公司累計涉及未審結/未調解訴訟案件23宗(包括本次披露的新增訴訟未審結案件;其中,公司及子公司為原告案件14宗,公司及子公司為被告案件9宗),未決訴訟案件涉案金額約為9.16億元(包括已披露的重大訴訟案件;其中,公司及子公司為原告案件涉案金額約1,725元,公司及子公司為被告涉案金額約8.98億元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.